title: [Clinical evaluation of autoantibody of splice variant of BARD1 in detection of ovarian cancer].
abstract: OBJECTIVE
  To investigate the value of autoantibody of breast cancer susceptibility 1-associated RING domain (BARD1) splice variant (OV-142) in detection of ovarian cancer.
  
  
  METHODS
  We cloned OV-142 gene into plasmid pET-30b(+). The recombinant protein of OV-142 was expressed in pET-30b(+) system and purified. The autoantibody of OV-142 was detected by indirect enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  We successfully constructed the recombinant plasmid of OV-142. The recombinant protein was expressed in pET-30b(+) system and purified. The purification rate of the recombinant protein was up to 90%. The relative amount of autoantibody of OV-142 detected by indirect ELISA was analyzed by receiver operating characteristic curve (ROC) and the cutoff value was determined. Combination of the autoantibody IgG of OV-142 and CA(125) was analyzed by logistic regression. The sensitivity, specificity and accuracy was 71.4%, 89.1%, and 81.9%, respectively, which were higher than IgG (41.3%, 84.2%, 66.8%) and CA(125) (61.1%, 88.0%, 77.1%) when used alone each.
  
  
  CONCLUSIONS
  OV-142 is a splice variant of BARD1. It may be a potential immunotherapy target of ovarian cancer. Detection of autoantibody of OV-142 is a potent complementary tool of CA(125) in ovarian cancer diagnosis.
authors.affiliation: Department of Gynecological Oncology, Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
authors.forename: Zhi-Jun
authors.initials: ZJ
authors.lastname: Yang
authors.forename: Yan-Ming
authors.initials: YM
authors.lastname: Jiang
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Yu-Liang
authors.initials: YL
authors.lastname: Ran
authors.forename: Zhi-Hua
authors.initials: ZH
authors.lastname: Yang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Jie-Qing
authors.initials: JQ
authors.lastname: Zhang
authors.forename: Zhong-Mian
authors.initials: ZM
authors.lastname: Pan
authors.forename: Li
authors.initials: L
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017398:Alternative Splicing; D000951:Antigens, Neoplasm / Q000097:blood*; D001323:Autoantibodies / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000235:genetics; D018394:CA-125 Antigen / Q000097:blood; D003001:Cloning, Molecular; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000235:genetics; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000235:genetics; D010957:Plasmids; D012680:Sensitivity and Specificity; D025521:Tumor Suppressor Proteins / Q000097:blood* / Q000235:genetics; D044767:Ubiquitin-Protein Ligases / Q000097:blood* / Q000235:genetics; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D018394:CA-125 Antigen; D007074:Immunoglobulin G; D025521:Tumor Suppressor Proteins; C102449:BARD1 protein, human; D044767:Ubiquitin-Protein Ligases